Literature DB >> 17664324

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.

Melissa E Boyne1, Todd J Sullivan, Christopher W amEnde, Hao Lu, Veronica Gruppo, Darragh Heaslip, Anita G Amin, Delphi Chatterjee, Anne Lenaerts, Peter J Tonge, Richard A Slayden.   

Abstract

Structure-based design was used to develop a focused library of A-ring-modified diphenyl ether InhA inhibitors. From this library of analogs, two high-affinity alkyl-substituted diphenyl ethers, 6PP and 8PP, were selected for advanced study into their in vitro activity against Mycobacterium tuberculosis clinical isolates, their in vivo properties, and their signature response mode of action. 6PP and 8PP demonstrated enhanced activity against whole bacteria and showed activity in a rapid macrophage model of infection. In addition, transcriptional profiling revealed that the A-ring modifications of 6PP and 8PP increased the specificity of each analog for InhA. Both analogs had substantially longer half-lives in serum than did the parent compound, exhibited a fivefold reduction in cytotoxicity compared to the parent compound, and were well tolerated when administered orally at 300 mg/kg of body weight in animal models. Thus, the A-ring modifications increased the affinity and whole-cell specificity of the compounds for InhA and increased their bioavailability. The next step in optimization of the pharmacophore for preclinical evaluation is modification of the B ring to increase the bioavailability to that required for oral delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664324      PMCID: PMC2043287          DOI: 10.1128/AAC.00383-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs.

Authors:  C E Barry; R A Slayden; A E Sampson; R E Lee
Journal:  Biochem Pharmacol       Date:  2000-02-01       Impact factor: 5.858

Review 2.  The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

Authors:  R A Slayden; C E Barry
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

3.  The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis.

Authors:  R A Slayden; C E Barry
Journal:  Tuberculosis (Edinb)       Date:  2002       Impact factor: 3.131

4.  The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action.

Authors:  Helena I M Boshoff; Timothy G Myers; Brent R Copp; Michael R McNeil; Michael A Wilson; Clifton E Barry
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

5.  Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis.

Authors:  B Heym; P M Alzari; N Honoré; S T Cole
Journal:  Mol Microbiol       Date:  1995-01       Impact factor: 3.501

6.  Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.

Authors:  R A Slayden; R E Lee; C E Barry
Journal:  Mol Microbiol       Date:  2000-11       Impact factor: 3.501

7.  High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.

Authors:  Todd J Sullivan; James J Truglio; Melissa E Boyne; Polina Novichenok; Xujie Zhang; Christopher F Stratton; Huei-Jiun Li; Tejinder Kaur; Amol Amin; Francis Johnson; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  ACS Chem Biol       Date:  2006-02-17       Impact factor: 5.100

8.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis.

Authors:  A Quémard; J C Sacchettini; A Dessen; C Vilcheze; R Bittman; W R Jacobs; J S Blanchard
Journal:  Biochemistry       Date:  1995-07-04       Impact factor: 3.162

9.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

10.  Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis.

Authors:  Xian-Zhi Li; Li Zhang; Hiroshi Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  27 in total

Review 1.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

3.  Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.

Authors:  Pan Pan; Susan E Knudson; Gopal R Bommineni; Huei-Jiun Li; Cheng-Tsung Lai; Nina Liu; Miguel Garcia-Diaz; Carlos Simmerling; Sachindra S Patil; Richard A Slayden; Peter J Tonge
Journal:  ChemMedChem       Date:  2014-03-11       Impact factor: 3.466

4.  Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.

Authors:  Kunal Kumar; Divya Awasthi; Seung-Yub Lee; Ilaria Zanardi; Bela Ruzsicska; Susan Knudson; Peter J Tonge; Richard A Slayden; Iwao Ojima
Journal:  J Med Chem       Date:  2010-12-02       Impact factor: 7.446

5.  The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.

Authors:  Luke C Kingry; Jason E Cummings; Kerry W Brookman; Gopal R Bommineni; Peter J Tonge; Richard A Slayden
Journal:  J Bacteriol       Date:  2012-11-09       Impact factor: 3.490

6.  Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.

Authors:  Catherine Vilchèze; Anthony D Baughn; JoAnn Tufariello; Lawrence W Leung; Mack Kuo; Christopher F Basler; David Alland; James C Sacchettini; Joel S Freundlich; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

7.  Structure-activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting Mtb-FtsZ as antitubercular agents.

Authors:  Krupanandan Haranahalli; Simon Tong; Saerom Kim; Monaf Awwa; Lei Chen; Susan E Knudson; Richard A Slayden; Eric Singleton; Riccardo Russo; Nancy Connell; Iwao Ojima
Journal:  RSC Med Chem       Date:  2020-10-16

8.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

9.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

10.  Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study.

Authors:  Pharit Kamsri; Auradee Punkvang; Patchareenart Saparpakorn; Supa Hannongbua; Stephan Irle; Pornpan Pungpo
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.